European Growth Stocks Insiders Are Betting On

As European markets show signs of recovery, with the STOXX Europe 600 Index snapping a two-week losing streak, investors are keeping a close watch on growth stocks that insiders are heavily investing in. In an environment where government spending hopes and trade tensions shape economic forecasts, companies with high insider ownership can signal confidence from those closest to their operations.

Top 10 Growth Companies With High Insider Ownership In Europe

Click here to see the full list of 238 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Stadler Rail (SWX:SRAIL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Stadler Rail AG, with a market cap of CHF2.15 billion, is involved in the manufacture and sale of trains across Switzerland, Germany, Austria, Western and Eastern Europe, the Americas, CIS countries, and internationally through its subsidiaries.

Operations: Stadler Rail's revenue is primarily derived from its Rolling Stock segment at CHF2.74 billion, followed by Service & Components at CHF866.43 million, and Signalling at CHF109.11 million.

Insider Ownership: 14.5%

Earnings Growth Forecast: 46.1% p.a.

Stadler Rail, with significant insider ownership, faces challenges as recent earnings show a decline in net income to CHF 38.42 million from CHF 124.32 million year-on-year, and profit margins have decreased to 1.2%. Despite this, the company is poised for substantial growth, with earnings expected to rise significantly at an annual rate of 46.1%, outpacing the Swiss market's average growth forecast of 11.1%.

• Get an in-depth perspective on Stadler Rail's performance by reading our analyst estimates report here.
• Our comprehensive valuation report raises the possibility that Stadler Rail is priced higher than what may be justified by its financials.

Fielmann Group (XTRA:FIE)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Fielmann Group AG operates in the optical and hearing aid sectors across Germany, Switzerland, Austria, and internationally with a market cap of €3.62 billion.

Operations: The company generates revenue of €2.16 billion from its medical-optical supplies segment.

Insider Ownership: 17.9%

Earnings Growth Forecast: 20.6% p.a.

Fielmann Group, with substantial insider ownership, is positioned for growth as its earnings are forecast to increase significantly by 20.6% annually over the next three years, surpassing the German market's average. Despite trading at a discount of 45.3% below fair value estimates and an unstable dividend history, analysts agree on a potential stock price rise of 29.4%. Recent management changes include Peter Lothes joining the board as a member, effective March 2025.

• Click here and access our complete growth analysis report to understand the dynamics of Fielmann Group.
• According our valuation report, there's an indication that Fielmann Group's share price might be on the cheaper side.

Redcare Pharmacy (XTRA:RDC)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Redcare Pharmacy NV operates as an online pharmacy across several European countries, including the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France with a market cap of €2.53 billion.

Operations: The company generates revenue through its DACH segment with earnings of €1.93 billion and its International segment with earnings of €436.50 million.

Insider Ownership: 11.7%

Earnings Growth Forecast: 47.8% p.a.

Redcare Pharmacy shows promising growth potential, with insiders actively buying shares recently. The company trades at a substantial discount of 58.6% below its estimated fair value, and revenue is expected to grow by 15.9% annually, outpacing the German market's average growth rate. Despite current losses, Redcare anticipates becoming profitable within three years and projects over 25% sales growth for 2025. Recent legal victories support its business model of offering bonuses on prescription orders.

• Unlock comprehensive insights into our analysis of Redcare Pharmacy stock in this growth report.
• The valuation report we've compiled suggests that Redcare Pharmacy's current price could be inflated.

Taking Advantage

• Get an in-depth perspective on all 238 Fast Growing European Companies With High Insider Ownership by using our screener here.
• Curious About Other Options? We've found 20 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com